Funding for this research was provided by:
First Online: 7 February 2020
Compliance with Ethical Standards
: Not applicable.
: T. Braun reports a stipend from the Köln Fortune program at Cologne University during the conduct of the study. J. von Jan has nothing to disclose. L. Wahnschaffe also receives support by the Köln Fortune program. Dr. Herling holds patents on TCL1 monoclonal antibodies (research and diagnostic use) with royalties paid.
: This article contains no studies with human or animal subjects performed by any of the authors.